{"id":192523,"name":"NOVARTIS CORPORATION","slug":"novartis-corporation","state":"DC","description":"research and development of products that protect &amp; improve health &amp; well-being","totalSpending":1220000,"filings":25,"yearlySpending":[{"year":2018,"income":320000},{"year":2019,"income":250000},{"year":2020,"income":150000},{"year":2021,"income":150000},{"year":2022,"income":200000},{"year":2024,"income":30000},{"year":2025,"income":120000}],"firms":["THORN RUN PARTNERS"],"lobbyists":["ALEX DELPIZZO","ANDREW ROSENBERG","GARY PALMQUIST","CHARLES THOMAS","JESSIE BRAIRTON","MICHAEL MCCARTHY","BEAU SCHUYLER","ELI KOGAN"],"issues":["MED","HCR","FOR","MMM","TAX","TRD"],"sampleDescriptions":["Issues related to biologics.","Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).\nNeonatal drug issues.","Legislation related to CFIUS and FARA including issues related to critical technologies and export controls;\nS.2098/H.R.4311, Foreign Investment Risk Review Modernization Act of 2017;\nS.2482, Foreign Agents Registration Amendments Act of 2018.","Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).\nIssues related to the Part D coverage gap and the Medicare reimbursement of biosimilars.","Issues related to the Orphan Drug Tax.","Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).\nIssues related to the Part D coverage gap and the Medicare reimbursement of biosimilars; H.R.1892, Bipartisan Budget Act of 2018 (P.L.115-123); H.R.1625, Consolidated Appropriations Act, 2018 (P.L.115-141).","Legislation related to CFIUS and FARA including issues related to critical technologies and export controls; S.2098/H.R.4311, Foreign Investment Risk Review Modernization Act of 2017; S.2482, Foreign Agents Registration Amendments Act of 2018.","Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs.","Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).","Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).\nIssues related to pharmaceutical pricing and biosimilars.","Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs.\nH.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.\nH.R. 19, Lower Costs, More Cures Act of 2019.","Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).\nIssues related to pharmaceutical pricing and biosimilars. \nH.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.\nH.R. 19, Lower Costs, More Cures Act of 2019.","Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs.\nThe Cares Act (P.L. 116-136).","Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).\nIssues related to pharmaceutical pricing and biosimilars. \nThe Cares Act (P.L. 116-136).","Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).\nIssues related to pharmaceutical pricing and biosimilars. \nH.R. 133, Consolidating Appropriations Act, 2021.","Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs.\nH.R. 133, Consolidating Appropriations Act, 2021.","Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).\nIssues related to pharmaceutical pricing and biosimilars.\nBuild Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.","Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs.\nBuild Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.","Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). Issues related to pharmaceutical pricing and biosimilars. Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.","Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs. Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031."],"years":[2018,2019,2020,2021,2022,2024,2025]}